DCOY Company Profile and Key Details

Decoy Therapeutics Inc. generated EPS of -$39.23 over the past year. Five-year average earnings growth is 57.63%. Wall Street analysts project EPS growth of 73.54% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.50 to $2.50. The high target offers -56.9% upside. The low target suggests -56.9% downside. The mean target is $2.50. This offers -56.9% upside. Decoy Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by -94.61%. The prior quarter beat by -79.55%. Over the last six quarters, Apple has recorded several small beats. These include -71.43% in March 21, 2025.

DCOY has shown mixed momentum, gaining 0.04% over the past week and -80.16% over the past quarter, though year-to-date performance is up 25.66%. Short-term trend indicators are bullishly aligned (SMA20 -6.37%, SMA50 -8.37%, SMA200 -87.47%). The stock’s 14-day RSI is 43.14 (neutral), while the ATR of 0.09 points to moderate volatility. The stock remains hovering near 52-week lows, trading -98.03% below its high and over 32.67% above its low. Average 10-day trading volume of 24.54 thousand shares is below the 3-month average of 197.97 thousand, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Decoy Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.62%, with price expected at $5.30 by April 16, 2026, within a range of $4.91 to $5.68 3-Month Outlook: Projected fall of -99.83%, reaching $0.01 by July 01, 2026, with a range of $0.00 to $0.18. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 02, 2027, within a range of $0.00 to $0.25.

Decoy Therapeutics Inc. (NASDAQ:DCOY) closed at $5.80 USD, losing -$0.52 (-8.23%) from the previous close of $6.32. The stock is currently within 5% of its 52-week low $5.60 and $415.80. With a market capitalization of about $3.09 million, Decoy Therapeutics Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.30). Key stats such as the average daily volume over the past year has been around 187.27 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Decoy Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Frederick E. Pierce, the company employs approximately 2 people and listed since January 29, 2015. Decoy Therapeutics, Inc. is a preclinical-stage biotechnology company that is leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.

Decoy Therapeutics Inc. (NASDAQ:DCOY) shares are up 25.66% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Decoy Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.22. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $2.50, suggesting -56.9% downside. Our AI forecast model points to short-term weakness (-8.62% over two weeks), a medium-term fall (-99.83% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Decoy Therapeutics Inc. trades at a P/E ratio of -0.22, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.47 suggesting the stock is closer to book value. The P/FCF stands at -0.64, also below market averages.